KoreaMed, a service of the Korean Association of Medical Journal Editors (KAMJE), provides access to articles published in Korean medical, dental, nursing, nutrition and veterinary journals. KoreaMed records include links to full-text content in Synapse and publisher web sites.
PURPOSE: Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV1)
Cho YK, Choi MG, Kim SH, Lee IS, Kim SW, Chung IS, Lee SY, Choi SC, Seol SY
KMID: 772622
Korean J Gastroenterol.
2004 Mar;43(3):160-167.
BACKGROUND/AIMS: It is unknown whether the prokinetics improve the quality of life in patients with functional dyspepsia. Thus, we evaluate the effect of the mosapride, selective 5-HT4 agonist, on...